BVCF

Cellenkos is a clinical-stage biotech company focused on the development and commercialization of transformative novel allogeneic Treg cell therapies to treat autoimmune and inflammatory disorders.

Oculis is a clinical-stage biotechnology company dedicated to developing innovative topical treatments for ophthalmic diseases affecting both the anterior and posterior segments of the eye. Founded in 2003 and headquartered in Reykjavik, Iceland, Oculis utilizes a unique drug delivery platform that enhances drug absorption through a novel technique, enabling effective treatment of conditions such as diabetic macular edema, uveitis, chronic dry eye syndrome, glaucoma, and diabetic retinopathy with simple eye drops. This approach allows for non-invasive treatment of diseases at the back of the eye, traditionally requiring more complex methods, while also reducing the frequency of applications needed for anterior eye conditions. Oculis is committed to improving patient outcomes and enhancing the quality of life for individuals with vision-related health issues.

Drug Farm is a China and US-based biotech developing innovative treatments targeting innate immunity for HBV, cancer, and autoimmune diseases. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments.

Boan Biotech is a biopharmaceutical company developing therapeutic antibodies with a focus on key therapeutic areas including oncology, metabolism, autoimmunity, and ophthalmology.

Seinda develops a point-of-care diagnosis platform for ophthalmic diagnosis and treatment. Seinda is committed to establishing an open ophthalmic omics platform, conducting molecular mechanism research on eye diseases, developing innovative diagnosis and treatment products, meeting clinical needs, gaining market premium, and building a world-class Chinese brand.

BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Founded in 2008 and headquartered in Mainz, Germany, the company has pioneered innovative therapies through advanced computational discovery and drug development platforms. BioNTech's oncology pipeline includes various neoantigen-targeted therapies, such as NEO-PV-01 for advanced non-small cell lung cancer and multiple FixVac product candidates for different cancers, including melanoma, prostate cancer, and HPV-positive head and neck cancers. The company also explores mRNA vaccine candidates for infectious diseases and maintains collaborations with prominent pharmaceutical firms. BioNTech Cell & Gene Therapies GmbH, a subsidiary, specializes in developing T cell immunotherapies for cancer treatment.

Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to developing therapies for diseases associated with mitochondrial dysfunction, which includes both rare genetic disorders and common age-related conditions. The company's lead product candidate, Elamipretide, aims to address these health issues, while additional candidates like SBT-20 and SBT-272 are being explored for their potential benefits in stabilizing mitochondrial function and treating neurodegenerative diseases, respectively. Founded in 2006 and based in George Town, Cayman Islands, Stealth BioTherapeutics collaborates with patients and advocacy groups to deepen its understanding of the challenges faced by those with mitochondrial diseases and to raise awareness of their therapeutic programs.

MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.

Genova (Changzhou) Biotechnology Co., Ltd. is a biotechnology company based in Changzhou, China, specializing in the development and manufacturing of insulin products. The company is dedicated to producing advanced insulin formulations aimed at treating diabetes, cardiovascular, and cerebrovascular diseases, as well as tumors. Genova focuses on providing third-generation insulin drugs to enhance patient care and improve treatment outcomes.

Eucure (Beijing) Biopharma Co., Ltd is a biotechnology company based in Beijing, China, specializing in the discovery and development of immuno-oncology targeted antibodies, particularly focusing on immune checkpoints. Founded in 2016, Eucure offers services including antibody production, in vivo drug efficacy testing, and in vitro efficacy evaluations. The company has a robust pipeline featuring multiple drug candidates, including YH-001 through YH-008. Several of these products have progressed to the CMC stage and have applied for clinical trials as of 2019. Eucure's mission is to create innovative antibody treatments aimed at improving survival rates for patients with tumors, reflecting its commitment to advancing cancer therapy. As of August 2020, Eucure operates as a subsidiary of Beijing Biocytogen Co., Ltd.

Eucure (Beijing) Biopharma Co., Ltd is a biotechnology company based in Beijing, China, specializing in the discovery and development of immuno-oncology targeted antibodies, particularly focusing on immune checkpoints. Founded in 2016, Eucure offers services including antibody production, in vivo drug efficacy testing, and in vitro efficacy evaluations. The company has a robust pipeline featuring multiple drug candidates, including YH-001 through YH-008. Several of these products have progressed to the CMC stage and have applied for clinical trials as of 2019. Eucure's mission is to create innovative antibody treatments aimed at improving survival rates for patients with tumors, reflecting its commitment to advancing cancer therapy. As of August 2020, Eucure operates as a subsidiary of Beijing Biocytogen Co., Ltd.

ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology and oncology. Founded in 2010, the company focuses on developing innovative treatments aimed at improving patient outcomes. Its clinical portfolio includes ASLAN004, a monoclonal antibody therapy for atopic dermatitis and other immunological conditions, as well as small molecule inhibitors targeting various cancer types. ASLAN collaborates with notable partners such as Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited to enhance its research and development efforts. The company is dedicated to creating novel medicines for both Asian and global markets.

DiaCarta provides precise cancer molecular tests including NRAS, EGFR and KRAS mutation test kits, PCR ready lysis kit, HPV E6/E7 mRNA test kits for cervical and head-neck cancer, cancer biomarker gene expression detection kits and superfast master mix. DiaCarta supplies precise molecular diagnostic cancer assays that enable the most sensitive, reliable, and accurate detection of cancer biomarkers directly from a patient sample, including QClamp gene mutation tests, SuperbDNA gene expression assays, and QZol, the only PCR ready lysate solution . DiaCarta's NRAS, EGFR, and KRAS tests are highly sensitive and able to detect a broad set of mutations and are being used by hospitals and cancer clinical laboratories for the treatment of patients and by biotechnology and pharmaceutical companies for clinical research.

CARsgen Therapeutics, Ltd., a clinical-stage immunotherapy company, develops and commercializes chimeric antigen receptor T-cell (CAR-T) therapeutics for treating cancers. It offers CAR-T Technology that directs T cells to recognize cancer cells based on expression of specific cell surface proteins to treat solid and hematologic tumors. The company’s CAR-T cells target the GPC3 receptor for the treatment of late-stage hepatocellular carcinoma (HCC, or liver cancer) and lung squamous cell carcinoma (a common type of lung cancer). CARsgen Therapeutics, Ltd. is based in Shanghai, China.

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company dedicated to developing gastrointestinal products for both human and animal use. The company operates through two segments: Human Health and Animal Health. Its human health pipeline includes crofelemer, currently in Phase III trials for treating cancer therapy-related diarrhea and for inflammatory bowel disease, as well as a formulation of crofelemer in Phase II trials for various gastrointestinal disorders. Additionally, it is developing SB-300, a second-generation anti-secretory agent. In the animal health segment, Jaguar Health offers Canalevia, aimed at treating chemotherapy-induced diarrhea in dogs, and Equilevia, a non-prescription product for equine gut health. The company also produces Neonorm Calf and Neonorm Foal. Founded in 2013 and headquartered in San Francisco, California, Jaguar Health focuses on providing naturally derived health solutions to a wide range of animals.

Suzhou Ribo Life Science is a developer of RNA interference ( RNAi ) technology designed to treat liver diseases. The company's RNA interference ( RNAi ) technology is used to develop nucleic acid therapeutic drugs and related products, enabling healthcare providers to deliver more effective pharmaceuticals to patients.

Genova (Changzhou) Biotechnology Co., Ltd. is a biotechnology company based in Changzhou, China, specializing in the development and manufacturing of insulin products. The company is dedicated to producing advanced insulin formulations aimed at treating diabetes, cardiovascular, and cerebrovascular diseases, as well as tumors. Genova focuses on providing third-generation insulin drugs to enhance patient care and improve treatment outcomes.

MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.